430. METHYLENE BLUE PART II: ANTIBACTERIAL, ANTI-LYME, AND ANTI-VIRAL EFFECTS

Methylene blue, first synthesized in 1876, is FDA‑approved only for methemoglobinemia but has been repurposed as a broad‑spectrum antimicrobial. Its redox‑cycling action simultaneously hijacks bacterial electron transport, generates reactive oxygen species, and penetrates biofilms, making it effective against stationary‑phase Borrelia burgdorferi and Bartonella persisters that evade conventional doxycycline or amoxicillin. Because the compound boosts mitochondrial ATP in human cells while starving microbes, low oral doses (4–50 mg twice daily) provide a therapeutic window that balances pathogen kill with patient safety.

Johns Hopkins screening identified methylene blue among the top 52 agents that eliminated ≥65 % of persister cells, rivaling intravenous daptomycin in potency yet remaining inexpensive and orally available. Subsequent studies confirmed similar activity against Bartonella biofilms and demonstrated synergistic effects when combined with rifampin or other antimicrobials. The drug also exhibits antiviral activity against HIV, hepatitis viruses, and SARS‑CoV‑2 in vitro, and retains anti‑malarial efficacy against Babesia‑like protozoa. Safety alerts focus on MAO‑A inhibition—relevant only for patients on SSRIs, SNRIs, or tramadol—and absolute contraindication in G6PD deficiency, a rarity in white populations.

For clinicians treating chronic Lyme or co‑infection, methylene blue offers a cost‑effective, pharmacy‑compounded option that bypasses the resistance mechanisms of traditional antibiotics. Its oxidative mechanism limits the emergence of tolerance, and long‑term urinary‑antiseptic use has been documented without significant adverse events. Practitioners should start at the lower end of the dosing range, monitor for serotonin syndrome in serotonergic patients, and inform anesthesiologists of ongoing therapy due to pulse‑oximeter interference. Ongoing clinical trials are needed to translate the robust in‑vitro data into definitive treatment guidelines.